Human HLA-DRA cDNA
Alternative name | DR alpha cDNA |
---|---|
Clone info. | Human HLA-DRA cDNA from EBV-B cells AKIBA library |
Vector backbone | pTZ18R (Plasmid) |
Size of vector backbone | 2.9 kb |
Selectable markers | Amp^r |
Gene/insert name | Human major histocompatibility complex, class II, DR alpha cDNA |
Depositor|Developer | Kimura, Akinori | Yasunami, Michiro | |
Additional map | ![]() |
---|
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment ![]() ![]() ![]() MTA, for use for not-for-profit academic purpose [Word ![]() ![]() MTA, for use for for-profit purpose [Word ![]() Please visit Information of Request for Distribution.[link] |
---|---|
Terms and conditions for distribution | For use of the BIOLOGICAL RESOURCE by a for-profit organization, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. |
Remarks | ((Additional form)) Approval Form(FormD) |
必要書類 | 提供依頼書 ![]() ![]() 提供同意書 (MTA, 非営利学術目的用)[Word ![]() ![]() 提供同意書 (MTA, 営利目的用)[Word ![]() 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
---|---|
MTAに書く使用条件 | 営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。研究成果の公表にあたって謝辞の表明を必要とする。 |
備考 | 【追加提供依頼書】承諾書(FormD) |
Catalog # | Resource name | Shipping form | Fee (non-profit org.) |
---|---|---|---|
RDB01232 | DRA2EH | DNA solution |
Materials & Methods section:
The DRA2EH was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB01232). |
Reference section:
Further references such as user reports and related articles (go to bottom)
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
Test sheet | RDB12737_A7Gsp1.pdf ![]() |
---|
Nucleotide sequence of a portion of this resource (if available).
Primer: HLA-DLA700F Sequence file: RDB12737_A7Gsa.seq ![]() |
---|
>01232_12737_A7Gs_HLA-DLA700F_B02_05_ABI24.ab1 1 CGTTACTTCA TTTCGAGCCA CGTGACATTG ACCACTGGTG GGGTGAACTT GTCTATGAAA 61 CAGATGAGGA CGTTGGGCTC TCTCAGTTCC ACAGGGCTGT TCGTGAGCAC AGTTACCTCT 121 GGAGGTACAT TGGTGATCGG AGTATAGTTG GAGCGCTTTG TCATGATTTC CAGGTTGGCT 181 TTGTCCACAG CTATGTTGGC CAATGCACCT TGAGCCTCAA AGCTGGCAAA TCGTCCAAAT 241 TCTTCAAGCC GCCAGACCGT CTCCTTCTTT GCCATATCCA CATGGAAAAT CTCATCACCA 301 TCAAAGTCAA ACATAAACTC GCCTGATTGG TCAGGATTCA GATAGAACTC GGCCTGGATG 361 ATCACATGTT CTTCTTTGAT AGCCCATGAT TCCTGAGCGC TCATCAGCAC AGCTATGATG 421 AAAAATCCTA GCACAGGGAC TCCACTTATG GCCATTTTCT TCTTGGGCGC CCCCCCCCCC 481 AAACCCCCCT GCAGGTCGAC TCTAGAGGAT CCCCGGGTAC CGAGCTCGAA TTCCCTATAG 541 TGAGTCGTAT TAAATTCGTA ATCATGTCAT AGCTGTTTCC TGTGTGAAAT TGTTATCCGC 601 TCACAATTCC ACACAACATA CGAGCCGGAA GCATAAAGTG TAAAGCCTGG GGTGCCTAAT 661 GAGTGAGCTA ACTCACATTA ATTGCGTTGC GCTCACTGCC CGCTTTCCAG TCGGGAAACC 721 TGTCGTGCCA GCTGCATTAA TGAATCGGCC AACGCGCGGG GAGAGGCGGT TTGCGTATTG 781 GGCGCTCTTC CGCTTCCTCG CTCACTGACT CGCTGCGCTC GGTCGTTCGG CTGCGGCGAG 841 CGGTATCAGC TCACTCAAAG GCGGTAATAC GGTTATCCAC AGAAATCAGG GGATAACGCA 901 GGAAAGAACA TGTGAGCAAA AGGCCAGCAA AAGGCCAGGA ACCGTAAAAA GGGCCGCGTT 961 GCTGGGCGTT TTTCCATAGG CTTCGCCCCC CCTGACGAGC ATCACAAAAA TCGACGCTCA 1021 AGGTCAGAGG TGGCGAAACC GGACAGGACT ATCAAGGATA CAGGCCGATC CCCCTTGTAG 1081 CTCCTCGTGC GCTCTCTGAT CGACCTGACG ACTTACG // |
Primer: HLA-DLA1200R Sequence file: RDB12737_A7Gsb.seq ![]() |
>01232_12737_A7Gs_HLA-DLA1200R_C02_08_ABI24.ab1 1 ATGCATTAAC ATAAAGTACA CAAGAGATGC CCCATGGGGC ATTCCATAGC AGAGACAGAC 61 TCCTGTATGT TTTATTCCAG AGGCATTGCA TGGTGATAAT AAAATGATAG GAAATAGAGG 121 AAAATAGATA CAGGAAAAGG CAATAGACAG GGAAGCCAGC TAGATGTTAG AGTACGGAGC 181 AATCGAGGAG GCATATCCAC ACTTGGGGTG GCTATAGGGC TGGAAAATGC TGAAGATGAC 241 TGCTTTCACT GAGGTCAAGG ATTGTAATAT TGCCAGCTTT GTAAAGCCAT TAAAGCAGAA 301 GTTTCTTCAG TGATCTTCTC TCTAAGAAAC ACCATCACCT CCATGTGCCT TACAGAGGCC 361 CCCTGCGTTC TGCTGCATTG CTTTTGCGCA ATCCCTTGAT GATGAAGATG GTCCCAATAA 421 TGATGCCCAC CAGACCCACA GTCAGGCCCA GGGCACACAC CACGTTCTCT GTAGTCTCTG 481 GGAGAGGGCT TGGAGCATCA AACTCCCAGT GCTTGAGAAG AGGCTCATCC AAGCCCCAGT 541 GCTCCACCCT GCAGTCGTAA ACGTCCTCAG TTGAGGGCAG GAAGGGGAGA TAGTGGAACT 601 TGCGGAAAAG GTGGTCTTCC CTGGGCAGGA AGACTGTCTC TGACACTCCT GTGGTGACAG 661 GTTTTCCATT TCGAAGCCAC GTGACATTGA CCACTGGTGG GGTGAACTTG TCTATGAAAC 721 AGATGAGGAC GTTGGGCTCT CTCAGTTCCA CAGGGCTGTT CGTGAGCACA GTTACCTCTG 781 GAGGTACATT GGTGATCGGA GTATAGTTGG AGCGCTTTGT CATGATTTCC AGGTTGGCTT 841 TGTCCACAGC TATGTTGGCC AATGCACCTT GAGCCTCAAA GCTGGCAAAT CGTCCAAATT 901 CTTCAAGCCG CCAGACCGTC TCCTTCTTTG CCATATCCAC ATGGAAAATC TCATCACCAT 961 CAAAGTCAAA CATAAACTCG CCCTGATTGG GTCAGGATTC AGATAGAAAC TCGGCCCTGG 1021 ATGATCACAT GTTCTTTCTT TGATAGCCCA TGATTCCCTG AAGCGCCAAT CATTAGCACA 1081 GGTACTTCCA CTATGGGCCA TTTTTCCTTC CTTG // |
Please visit Sequencing and PCR primers for primer information.
Original, user report and related articles
Featured content